Medexus Pharmaceuticals Inc. (MEDXF)
| Previous Close | 1.2150 |
| Open | 1.2670 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.2550 - 1.3032 |
| 52 Week Range | 0.8380 - 2.5620 |
| Volume | |
| Avg. Volume | 18,582 |
| Market Cap | 31.796M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | 4.48 |
| EPS (TTM) | 0.2900 |
| Earnings Date | Feb 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
NewsfileMedexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024 Bloom Burton & Co. Healthcare Investor ConferenceDate: April 16-17, 2024Location: Toronto, OntarioMedexus Presentation: Wednesday, April 17 at 1:30 PM Eastern timeKen d'Entremont, Medexus's Chief Executive
NewsfileFDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-dem
Simply Wall St.Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Slashed Next Year's Estimates
The analysts covering Medexus Pharmaceuticals Inc. ( TSE:MDP ) delivered a dose of negativity to shareholders today, by...
